{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:55Z","timestamp":1790806855167,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1038\/s41433-021-01413-4","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T13:26:09Z","timestamp":1611926769000},"page":"3302-3310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The results of intravitreal bevacizumab monotherapy for treating aggressive posterior retinopathy of prematurity and Type 1 retinopathy of prematurity"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2628-9426","authenticated-orcid":false,"given":"Ay\u015feg\u00fcl","family":"\u00c7\u00f6mez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yal\u00e7\u0131n","family":"Karak\u00fc\u00e7\u00fck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet C\u00fcneyt","family":"\u00d6zmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pelin","family":"\u00c7elemler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O\u011fuzhan","family":"Sayg\u0131l\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"1413_CR1","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1172\/JCI42142","volume":"120","author":"P Sapieha","year":"2010","unstructured":"Sapieha P, Joyal J, Rivera JC, Kermorvant-Duchemin E, Sennlaub F, Hardy P, et al. Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. J Clin Invest. 2010;120:3022\u201332. https:\/\/doi.org\/10.1172\/JCI42142","journal-title":"J Clin Invest"},{"key":"1413_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/aos.12049","volume":"92","author":"G Cavallaro","year":"2014","unstructured":"Cavallaro G, Filippi L, Bagnoli P, La Marca G, Cristofori G, Raffaeli G, et al. The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge. Acta Ophthalmol. 2014;92:2\u201320. https:\/\/doi.org\/10.1111\/aos.12049","journal-title":"Acta Ophthalmol"},{"key":"1413_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/pr.2013.205.4","volume":"1","author":"H Blencowe","year":"2013","unstructured":"Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res. 2013;1:35\u201349. https:\/\/doi.org\/10.1038\/pr.2013.205.4","journal-title":"Pediatr Res"},{"key":"1413_CR4","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative Group.","year":"2003","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684\u201394.","journal-title":"Arch Ophthalmol"},{"key":"1413_CR5","first-page":"233","volume":"102","author":"WV Good","year":"2004","unstructured":"Good WV, Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233\u201348. discussion 248-50","journal-title":"Trans Am Ophthalmol Soc"},{"key":"1413_CR6","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014;132:1327\u201333. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.2772. BEAT-ROP Cooperative Group","journal-title":"JAMA Ophthalmol"},{"key":"1413_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage3+ retinopathy of prematurity. N Engl J Med. 2011;364:603\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1007374","journal-title":"N Engl J Med"},{"key":"1413_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","volume":"124","author":"DK Vander Veen","year":"2017","unstructured":"Vander Veen DK, Melia M, Yang MB, Hutchinson AK, Wilson LB, Lambert SR. Anti-vascular endothelial growth factor therapy for primary treatment of Type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology. Ophthalmology. 2017;124:619\u201333. https:\/\/doi.org\/10.1016\/j.ophtha.2016.12.025","journal-title":"Ophthalmology."},{"key":"1413_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10456-007-9066-0","volume":"10","author":"J Chen","year":"2007","unstructured":"Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007;10:133\u201340. https:\/\/doi.org\/10.1007\/s10456-007-9066-0","journal-title":"Angiogenesis"},{"key":"1413_CR10","doi-asserted-by":"publisher","first-page":"CD009734","DOI":"10.1002\/14651858.CD009734.pub2","volume":"2","author":"MJ Sankar","year":"2016","unstructured":"Sankar MJ, Sankar J, Mehta M, Bhat V, Srinivasan R. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev. 2016;2:CD009734 https:\/\/doi.org\/10.1002\/14651858.CD009734.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1413_CR11","doi-asserted-by":"publisher","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","volume":"10","author":"L Pertl","year":"2015","unstructured":"Pertl L, Steinwender G, Mayer C, Hausberger S, P\u00f6schl EM, Wackernagel W, et al. A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS One. 2015;10:e0129383 https:\/\/doi.org\/10.1371\/journal.pone.0129383","journal-title":"PLoS One"},{"key":"1413_CR12","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jaapos.2016.10.002","volume":"20","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner HA. Retinopathy of prematurity: intravitreal injections of bevacizumab: timing, technique, and outcomes. J AAPOS. 2016;20:478\u201380. https:\/\/doi.org\/10.1016\/j.jaapos.2016.10.002","journal-title":"J AAPOS"},{"key":"1413_CR13","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity.","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of Prematurity. The international Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123:991\u20139. https:\/\/doi.org\/10.1001\/archopht.123.7.991","journal-title":"Arch Ophthalmol"},{"key":"1413_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/bf02482615","volume":"74","author":"EA Palmer","year":"1990","unstructured":"Palmer EA. Results of U.S. randomized clinical trial of cryotherapy for ROP(CRYO-ROP). Doc Ophthalmol. 1990;74:245\u201351. https:\/\/doi.org\/10.1007\/bf02482615","journal-title":"Doc Ophthalmol"},{"key":"1413_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jaapos.2013.01.004.","volume":"17","author":"S Ittiara","year":"2013","unstructured":"Ittiara S, Blair MP, Shapiro MJ, Lichtenstein SJ. Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab. J AAPOS. 2013;17:323\u20135. https:\/\/doi.org\/10.1016\/j.jaapos.2013.01.004.","journal-title":"J AAPOS"},{"key":"1413_CR16","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/archophthalmol.2011.1802","volume":"130","author":"RD Patel","year":"2012","unstructured":"Patel RD, Blair MP, Shapiro MJ, Lichtenstein SJ. Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity. Arch Ophthalmol. 2012;130:801\u20132. https:\/\/doi.org\/10.1001\/archophthalmol.2011.1802","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"1413_CR17","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130(8):1000\u20136. https:\/\/doi.org\/10.1001\/archophthalmol.2012.592. Erratum in: Arch Ophthalmol. 2013;131:212.","journal-title":"Arch Ophthalmol"},{"key":"1413_CR18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3928\/23258160-20160229-12.","volume":"47","author":"LL Snyder","year":"2016","unstructured":"Snyder LL, Garcia-Gonzalez JM, Shapiro MJ, Blair MP. Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging Retin. 2016;47:280\u20133. https:\/\/doi.org\/10.3928\/23258160-20160229-12.","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"key":"1413_CR19","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/IAE.0b013e3181a68f3a","volume":"29","author":"G Sanghi","year":"2009","unstructured":"Sanghi G, Dogra MR, Das P, Vinekar A, Gupta A, Dutta S. Aggressive posterior retinopathy of prematurity in Asian Indian babies: spectrum of disease and outcome after laser treatment. Retina. 2009;29:1335\u20139. https:\/\/doi.org\/10.1097\/IAE.0b013e3181a68f3a","journal-title":"Retina"},{"key":"1413_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/IAE.0b013e3181cb6151","volume":"30","author":"KA Drenser","year":"2010","unstructured":"Drenser KA, Trese MT, Capone A Jr. Aggressive posterior retinopathy of prematurity. Retina. 2010;30:37\u201340. https:\/\/doi.org\/10.1097\/IAE.0b013e3181cb6151","journal-title":"Retina"},{"key":"1413_CR21","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00417-014-2867-0","volume":"253","author":"H Yetik","year":"2015","unstructured":"Yetik H, Gunay M, Sirop S, Salihoglu Z. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity \u2013 27 month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol. 2015;253:1677\u201383. https:\/\/doi.org\/10.1007\/s00417-014-2867-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1413_CR22","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","volume":"38","author":"JM Garcia Gonzalez","year":"2018","unstructured":"Garcia Gonzalez JM, Snyder L, Blair M, Rohr A, Shapiro M, Greenwald M. Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity. Retina. 2018;38:764\u201372. https:\/\/doi.org\/10.1097\/IAE.0000000000001581","journal-title":"Retina"},{"key":"1413_CR23","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00417-020-04605-y","volume":"258","author":"MA Mart\u00ednez-Castellanos","year":"2020","unstructured":"Mart\u00ednez-Castellanos MA, Gonz\u00e1lez-H Le\u00f3n A, Romo-Aguas JC, Gonzalez-Gonzalez LA. A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series. Graefes Arch Clin Exp Ophthalmol. 2020;258:767\u201372. https:\/\/doi.org\/10.1007\/s00417-020-04605-y","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1413_CR24","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","volume":"122","author":"CK Hwang","year":"2015","unstructured":"Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015;122:1008\u201315. https:\/\/doi.org\/10.1016\/j.ophtha.2014.12.017","journal-title":"Ophthalmology."},{"key":"1413_CR25","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663.","volume":"40","author":"KP Ling","year":"2020","unstructured":"Ling KP, Liao PJ, Wang NK, Chao AN, Chen KJ, Chen TL, et al. Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy. Retina. 2020;40:1793\u2013803. https:\/\/doi.org\/10.1097\/IAE.0000000000002663.","journal-title":"Retina"},{"key":"1413_CR26","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","volume":"123","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology. 2016;123:1845\u201355. https:\/\/doi.org\/10.1016\/j.ophtha.2016.04.028","journal-title":"Ophthalmology."},{"key":"1413_CR27","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00417-019-04292-4","volume":"257","author":"I Perente","year":"2019","unstructured":"Perente I, Eris E, Seymen Z, Cevik SG, Bekmez S. Aggressive posterior retinopathy of prematurity treated with intravitreal bevacizumab: late period fluorescein angiographic findings. Graefes Arch Clin Exp Ophthalmol. 2019;257:1141\u20136. https:\/\/doi.org\/10.1007\/s00417-019-04292-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1413_CR28","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","volume":"98","author":"SG Tahija","year":"2014","unstructured":"Tahija SG, Hersetyati R, Lam GC, Kusaka S, McMenamin PG. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol. 2014;98:507\u201312. https:\/\/doi.org\/10.1136\/bjophthalmol-2013-304109","journal-title":"Br J Ophthalmol"},{"key":"1413_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","volume":"37","author":"B Lorenz","year":"2017","unstructured":"Lorenz B, Stieger K, J\u00e4ger M, Mais C, Stieger S, Andrassi-Darida M. Retinal vascular development with 0.312 MG intravitrealbevacizumab to treat severe posterior retinopathy OF prematurity: a longitudinal fluorescein angiographic study. Retina. 2017;37:97\u2013111. https:\/\/doi.org\/10.1097\/IAE.0000000000001126","journal-title":"Retina"},{"key":"1413_CR30","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1097\/IAE.0000000000001685","volume":"38","author":"Y Yonekawa","year":"2018","unstructured":"Yonekawa Y, Wu WC, Nitulescu CE, Chan RVP, Thanos A, Thomas BJ, et al. Progressive retinal detachment in infants with retinopathy of prematurity treated with intravitreal bevacizumab or ranibizumab. Retina. 2018;38:1079\u201383. https:\/\/doi.org\/10.1097\/IAE.0000000000001685","journal-title":"Retina"},{"key":"1413_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ajo.2018.09.039.","volume":"198","author":"TA Chen","year":"2019","unstructured":"Chen TA, Shields RA, Bodnar ZH, Callaway NF, Schachar IH, Moshfeghi DM. A spectrum of regression following intravitreal bevacizumab in retinopathy of prematurity. Am J Ophthalmol. 2019;198:63\u201369. https:\/\/doi.org\/10.1016\/j.ajo.2018.09.039.","journal-title":"Am J Ophthalmol"},{"key":"1413_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000000887","author":"S Tanaka","year":"2019","unstructured":"Tanaka S, Yokoi T, Katagiri S, Yoshida T, Nishina S, Azuma N. Severe recurrent fibrovascular proliferation after combined intravitreal bevacizumab injection and laser photocoagulation for aggressive posterior retinopathy of prematurity. Retin Cases Brief Rep. 2019. https:\/\/doi.org\/10.1097\/ICB.0000000000000887. Epub ahead of print 17 July","journal-title":"Retin Cases Brief Rep"},{"key":"1413_CR33","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1083\/jcb.200302047","volume":"161","author":"H Gerhardt","year":"2003","unstructured":"Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003;161:1163\u201377. https:\/\/doi.org\/10.1083\/jcb.200302047","journal-title":"J Cell Biol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01413-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01413-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01413-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:12:56Z","timestamp":1684617176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01413-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1413"],"URL":"https:\/\/doi.org\/10.1038\/s41433-021-01413-4","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]},"assertion":[{"value":"17 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}